Immunochemical AAV studies
Anti-AAV virus particle antibodies are suitable for the characterisation of different stages of adeno-associated virus (AAV) infection and are very useful for the analysis of the AAV capsid assembly. The antibodies specifically recognize conformational epitopes in assembled capsids of different AAV serotypes. Hence, they exclusively react with intact AAV particles.
Viral capsid protein antibodies (VP) exclusively recognize AAV capsid proteins and are useful for immunolocalization studies of AAV capsid formation, or immunoprecipitation and western blot analysis of viral capsid proteins. Anti-AAV replicase antibodies (Rep) react with selected replicase (Rep) proteins in human AAV-infected cells. Applications include immunolocalization or immunoblotting studies to investigate the correlation between Rep expression and the course of an infection.
AAV antibodies in gene therapy research
AAV vectors are powerful tools in gene therapy research and development. Recombinant AAV vectors (rAAV) corresponding to the different viral serotypes have successfully been used as universal gene shuttles in human cells.1 Neutralizing AAV antibodies present in serum or plasma may block transduction with AAV vectors.
In a prescreening step before vector administration, the titer of neutralizing AAV antibodies can be determined in a cell-based assay. PROGEN's AAV antibodies are ideal positive controls that neutralize wild-type AAV capsids of AAV serotypes 1, 2, 5, 6, 8, and 9.2-7
PROGEN supplements its portfolio of AAV antibodies with advanced recombinant IgGs that feature optimal stability and batch-to-batch consistency. These antibodies retain equal performance compared to the mouse monoclonal antibodies with respect to cross-reactivity, AAV capsid recognition and binding sensitivity (see figure below).
|Comparison of PROGEN's A20 mouse monoclonal antibody with the recombinant A20R antibody (both against AAV2): A) Dot blot comparing cross-reactivities of A20 and A20R with different AAV serotypes. B) Dot blot analysis of antibody reactivity with denatured and native AAV2 capsids. C) Dot blot analysis of binding sensitivity of A20 and A20R by using decreasing AAV2 particle titers.